Clinical Application of LCBP Risk Assessment Model in Risk Stratification of Pulmonary Nodules
DOI:
https://doi.org/10.53469/jcmp.2025.07(02).29Keywords:
Pulmonary nodules, Biomarkers, Imaging, LCBP risk assessment modelAbstract
Objective: To use the LCBP risk assessment model to evaluate tumor markers combined with imaging diagnosis, stratify the risk of pulmonary nodules, and predict the probability of disease malignancy in patients. Methods: A total of 80 patients with pulmonary nodules on lung CT examination in the Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine from January 2020 to April 2021 were enrolled as the experimental group, and 60 patients without pulmonary nodules were selected as the control group. Blood samples were collected from patients without treatment, and ProGRP, CEA, SCC-AG and CYFRA21-1 serum biomarkers were determined by chemiluminescence immunoassay. Results: There were statistically significant differences in serological markers between the two groups (P<0.05), and the evaluation of the malignant probability of pulmonary nodules by imaging indicators and the presence or absence of burr signs were statistically significant (P<0.05). The AUC of the low-risk group was 0.761, the AUC of the intermediate-risk group was 0.749, and the AUC of the high-risk group was 0.804. Conclusion: The LCBP risk assessment model based on serological markers, imaging findings and clinical data has a good ability to distinguish the risk stratification of pulmonary nodules
References
ZHAO Mingwei. Differential diagnostic value of lung CT examination on the benign and malignant nature of ground-glass nodule-like lungs[J]. Sichuan Journal of Physiological Sciences, 2024, 46(4):849-851.
CUI Xiaonan, YE Zhaoxiang. Predictive modelling of lung nodule pathology based on preoperative CT images [J]. Chinese Journal of Radiology, 2024, 58(2): 243-244.
Shen Aijun, Li Hongjiang, Xia Ganlin, et al. CT imaging features of malignant isolated pulmonary nodules [J]. Chinese Journal of Practical Diagnosis and Therapy, 2013, 27(012): 1209-1211.
HATT M, TIXIER F, PIERCE L, et al. Characterization of PET/CT images using texture analysis: the past, the present any future [J]. Eur J Nucl Med Mol Imaging, 2017, 44(1): 151-165.
OHRI N, DUAN F, SNYDER B S, et al. Pretreatment 18F-FDG PET Textural Features in Locally Advanced Non-Small Cell Lung Cancer: Secondary Analysis of ACRIN 6668/RTOG 0235 [J]. J Nucl Med, 2016, 57(6): 842-848.
PERANDINI S, SOARDI G A, MOTTON M, et al. Solid pulmonary nodule risk assessment and decision analysis: comparison of four prediction models in 285 cases [J]. Eur Radiol, 2016, 26(9): 3071-3076.
WANG Xin, XU Yuehua, DU Ziyan, et al. CT imaging features of isolated pulmonary nodules and the establishment of benign and malignant prediction model [J]. Chinese Journal of Oncology, 2018, 40(002): 115-120.
LI Y, CHEN K Z, WANG J. Development and validation of a clinical prediction model to estimate the probability of malignancy in solitary pulmonary nodules in Chinese people [J]. Clin Lung Cancer, 2011, 12(5): 313-319.
AN Yang, LI Chunzhao, ZHAO Wei. Validation study of three lung cancer risk prediction models in patients with lung nodules [J]. Journal of PLA Medical College, 2020, 41(12): 2095-2097.
YANG D, ZHANG X, POWELL C A, et al. Probability of cancer in high-risk patients predicted by the protein-based lung cancer biomarker panel in China: LCBP study [J]. Cancer, 2018, 124(2): 262-270.
Jia Bo, Wang Zi Ping. Progress of emerging biomarkers for lung cancer treatment with immune checkpoint inhibitors[J]. China Cancer Clinics and Rehabilitation, 2023, 30(5):287-294.
Yanyan Qiao, FU Enqing. Research progress of tumour-associated macrophages in lung cancer[J]. Chinese Journal of Lung Cancer, 2022, 25(1):34-39.
SHIN K E, LEE K S, YI C A, et al. Subcentimeter lung nodules stable for 2 years at LDCT: long-term follow-up using volumetry [J]. Respirology, 2014, 19(6): 921-928.
SINGH H, SETHI S, RABER M, et al. Errors in cancer diagnosis: current understanding and future directions [J]. J Clin Oncol, 2007, 25(31): 5009-5018.
Bing Zhang, C G Hu. Three-dimensional CT bronchial angiography thoracoscopic segmental lung resection for T 1a~1bN 0M 0 stage non-small cell lung cancer [J]. Oncology Research and Clinics, 2023, 35(9):706-709.
MAZZONE P J, SEARS C R, ARENBERG D A, et al. Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use an Official American Thoracic Society Policy Statement [J]. Am J Respir Crit Care Med, 2017, 196(7): 15-29.
Tingting Zhang, Yi Xiang, Yubing Lin. Predictive value of combined detection of tumor markers in the diagnosis of lung cancer[J]. Zhonghua Yu Fang Yi Xue Za Zhi, 2021, 55(6):786-791.
Wu HY, Pan YY, Kopylov AT, Zgoda V, Ma MC, Wang CH, Su WC, Lai WW, Cheng PN, Liao PC. Assessment of Serological Early Biomarker Candidates for Lung Adenocarcinoma by using Multiple Reaction Monitoring-Mass Spectrometry[J]. Proteomics Clin Appl, 2020, 14(4):e-1900-1905.
Gao J, Zhang L, Peng K, Sun H. [Diagnostic value of serum tumor markers CEA, CYFRA21-1, SCCAg, NSE and ProGRP for lung cancers of different pathological types]. Nan Fang Yi Ke Da Xue Xue Bao, 2022, 42(6):886-891.
Wang R. Clinical value of low-dose spiral CT in lung cancer screening [J]. Imaging Research and Medical Applications, 2019, 3(18): 18-21.
Huo Dandan. Analysis of the value of individual and combined detection of four lung cancer serum tumour markers in lung cancer diagnosis [J]. China Emergency Medicine, 2018, 038(0z1): 75-80.
Wu H, Wang Q, Liu Q, Zhang Q, Huang Q, Yu Z. The Serum Tumor Markers in Combination for Clinical Diagnosis of Lung Cancer[J]. Clin Lab, 2020, 66(3):1905-1909.
Huang J, Ren K. Detection of Changes in CEA and ProGRP Levels in BALF of Patients with Peripheral Lung Cancer and the Relationship with CT Signs[J]. Contrast Media Mol Imaging, 2023, 2(18):1421-1429.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Baojing Liu, Yiwen Shi, Ziwei Zhang, Minglan Liu, Rui Sun, Yanxia Ma, Zhanzheng Wang
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
